Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor

Por Eskens, Ferry ALM, Haberkorn, Brigitte
Publicado no Transl Androl Urol (2012)

The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation

Por Lolkema, Martijn P., Bohets, Hilde H., Arkenau, Hendrik-Tobias, Lampo, Ann, Barale, Erio, de Jonge, Maja J.A., van Doorn, Leni, Hellemans, Peter, de Bono, Johann S., Eskens, Ferry A.L.M.
Publicado no Clin Cancer Res (2015)

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

Por van der Biessen, Diane A.J., Cranendonk, Merlijn A., Schiavon, Gaia, van der Holt, Bronno, Wiemer, Erik A.C., Eskens, Ferry A.L.M., Verweij, Jaap, de Jonge, Maja J.A., Mathijssen, Ron H.J.
Publicado em 2013

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

Por Cainap, Calin, Qin, Shukui, Huang, Wen-Tsung, Chung, Ik Joo, Pan, Hongming, Cheng, Ying, Kudo, Masatoshi, Kang, Yoon-Koo, Chen, Pei-Jer, Toh, Han-Chong, Gorbunova, Vera, Eskens, Ferry A.L.M., Qian, Jiang, McKee, Mark D., Ricker, Justin L., Carlson, Dawn M., El-Nowiem, Saied
Publicado no J Clin Oncol (2015)

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

Por de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A.L.M., Wiemer, Erik A.C., Verweij, Jaap, Mathijssen, Ron H.J., van Schaik, Ron H.N.
Publicado em 2013